|
市場調査レポート
商品コード
1511330
アミノフィリンの世界市場、2030年までの予測：投与経路別、流通チャネル別、用途別、地域別Aminophylline Market Forecasts to 2030 - Global Analysis By Route of Administration, Distribution Channel, Application and By Geography |
||||||
カスタマイズ可能
|
|||||||
| アミノフィリンの世界市場、2030年までの予測：投与経路別、流通チャネル別、用途別、地域別 |
|
出版日: 2024年07月06日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 図表
- 目次
Stratistics MRCによると、アミノフィリンの世界市場は2024年に2億9,930万米ドルを占め、予測期間中にCAGR 2.8％で成長し、2030年には3億5,320万米ドルに達すると予想されています。
アミノフィリンは、気道の筋肉を弛緩させ呼吸を改善することにより、喘息、慢性気管支炎、その他の呼吸器疾患の治療に使用される気管支拡張薬です。アミノフィリン市場は、呼吸器疾患の有病率の上昇や医療ニーズの高まりを背景に、病院、クリニック、在宅ケアの現場で使用されています。経口投与、静脈内投与、注射が可能で、治療域が狭いため慎重な投与量のモニタリングが必要です。
世界保健機関（WHO）のデータによると、呼吸器疾患は世界的に主要な死因となっています。同様に、2023年のEconomic Timesの記事は、喘息患者が世界的に増加し、約3億3,900万人が罹患していることを強調しています。
高齢化人口の増加
高齢化人口の増加は、アミノフィリン市場の重要な促進要因です。高齢化に伴い、喘息や慢性閉塞性肺疾患（COPD）などの慢性呼吸器疾患を発症する可能性が高くなります。気管支拡張薬であるアミノフィリンは、気道の筋肉を弛緩させ呼吸を改善することで、これらの疾患を管理するために一般的に使用されています。呼吸器疾患にかかりやすい高齢者の増加がアミノフィリンの需要を押し上げ、市場の成長に寄与しています。
厳しい規制要件
厳しい規制要件は、アミノフィリン市場に大きな抑制要因となっています。アミノフィリンを含む医薬品の承認プロセスには、厳格な試験とFDAやEMAなどの規制機関によって設定された安全性と有効性の基準への準拠が含まれます。これらの厳しい規制は、製品承認の遅延や製造業者のコスト増につながる可能性があります。このような複雑な規制の枠組みを遵守する必要があるため、アミノフィリン製剤のタイムリーな導入が妨げられ、市場の成長が抑制される可能性があります。
呼吸器疾患の有病率の増加
呼吸器疾患の有病率の増加は、アミノフィリン市場に大きな機会をもたらします。喘息、COPD、気管支炎などの疾患は、公害、喫煙、ライフスタイルの変化などの要因のために、より一般的になってきています。アミノフィリンは、これらの症状に対する効果的な治療薬であり、症状を緩和し、生活の質を向上させるのに役立ちます。呼吸器疾患の罹患率の上昇がアミノフィリンの需要を牽引し、市場拡大と新しい治療製剤の開発の機会を生み出しています。
副作用と安全性への懸念
アミノフィリンの使用に伴う副作用と安全性の懸念が、市場に脅威を与えています。一般的な副作用には吐き気、嘔吐、頭痛、不眠症などがあるが、重篤な反応としては不整脈や痙攣発作などがあります。これらの副作用はアミノフィリンの使用を制限する可能性があり、患者や医療提供者はよりリスクの少ない代替治療を選択する可能性があります。製剤の改良と患者教育を通じてこうした安全性の懸念に対処することが、市場の成長を維持する上で極めて重要です。
COVID-19の影響：
COVID-19の大流行はアミノフィリン市場にさまざまな影響を与えました。呼吸器の健康への注目がアミノフィリンのような治療への需要を高めた一方で、サプライチェーンや医療サービスの混乱は生産と流通に影響を与えました。パンデミックは効果的な呼吸器治療の重要性を浮き彫りにし、医療システムが回復して呼吸器治療を優先するにつれて、アミノフィリンの将来の需要を促進する可能性があります。
予測期間中、経口剤セグメントが最大となる見込み
経口セグメントは、その利便性と広範な使用により、アミノフィリン市場を独占すると予測されます。錠剤やカプセルの形態でのアミノフィリンの経口投与は、その使いやすさと非侵襲性から患者に好まれています。このセグメントの成長の原動力は、慢性呼吸器疾患の有病率の増加と、一貫した投与が可能で患者のコンプライアンスが向上する経口薬への嗜好です。
オンライン薬局セグメントは予測期間中最も高いCAGRが見込まれる
オンライン薬局分野は、デジタルヘルスケアとeコマースの動向の高まりにより、CAGRが最も高くなると予測されます。オンラインでの医薬品購入の利便性と、医療サービスにおけるデジタルプラットフォームの利用の増加が、このセグメントの成長を牽引しています。オンライン薬局は、特に遠隔地の患者や慎重な購入オプションを求める患者にとって、アミノフィリンへの容易なアクセスを提供し、このセグメントの急速な拡大に寄与しています。
最大のシェアを占める地域
北米は、高度なヘルスケア・インフラを有し、呼吸器疾患の有病率が高いことから、アミノフィリン市場を独占する立場にあります。この地域は医療研究施設が確立されており、革新的な治療に力を入れているため、アミノフィリンの需要が高まっています。さらに、大手製薬会社の存在と多額の医療支出が、北米の市場における主導的地位をさらに強化しています。
CAGRが最も高い地域：
アジア太平洋地域は、都市化の進展、汚染レベルの上昇、高齢化人口の増加により、アミノフィリン市場の急成長が見込まれています。中国やインドなどの国々では呼吸器疾患が急増しており、アミノフィリンのような効果的な治療に対する需要が高まっています。医療インフラを改善するための政府の取り組みと医薬品製造能力の拡大は、アジア太平洋地域の高いCAGRに貢献しています。
無料のカスタマイズ提供：
本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：
- 企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
- 地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
- 競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング
目次
第1章 エグゼクティブサマリー
第2章 序文
- 概要
- ステークホルダー
- 調査範囲
- 調査手法
- データマイニング
- データ分析
- データ検証
- 調査アプローチ
- 調査情報源
- 1次調査情報源
- 2次調査情報源
- 前提条件
第3章 市場動向分析
- 促進要因
- 抑制要因
- 機会
- 脅威
- 用途分析
- 新興市場
- COVID-19の影響
第4章 ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入業者の脅威
- 競争企業間の敵対関係
第5章 世界のアミノフィリン市場：投与経路別
- 経口
- 静脈内
- 注射
第6章 世界のアミノフィリン市場：流通チャネル別
- 病院
- クリニック
- 外来手術センター
- 小売薬局
- オンライン薬局
第7章 世界のアミノフィリン市場：用途別
- 喘息治療
- 慢性閉塞性肺疾患（COPD）治療
- 乳児の無呼吸発作
- その他
第8章 世界のアミノフィリン市場：地域別
- 北米
- 米国
- カナダ
- メキシコ
- 欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
- アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
- 南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
- 中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東・アフリカ
第9章 主な発展
- 契約、パートナーシップ、コラボレーション、合弁事業
- 買収と合併
- 新製品発売
- 事業拡大
- その他の主要戦略
第10章 企業プロファイリング
- GlaxoSmithKline plc
- Altor BioScience Corporation
- Ono Pharmaceutical
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Biosynth
- Pfizer Inc.
- Abcam plc
- Henry Schein, Inc.
- Medline Industries, Inc.
- Boehringer Ingelheim
- Novartis AG
- Sanofi S.A.
- AstraZeneca plc
- Merck & Co., Inc.
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Zydus Cadila
List of Tables
- Table 1 Global Aminophylline Market Outlook, By Region (2022-2030) ($MN)
- Table 2 Global Aminophylline Market Outlook, By Route of Administration (2022-2030) ($MN)
- Table 3 Global Aminophylline Market Outlook, By Oral (2022-2030) ($MN)
- Table 4 Global Aminophylline Market Outlook, By Intravenously (2022-2030) ($MN)
- Table 5 Global Aminophylline Market Outlook, By Injections (2022-2030) ($MN)
- Table 6 Global Aminophylline Market Outlook, By Distribution Channel (2022-2030) ($MN)
- Table 7 Global Aminophylline Market Outlook, By Hospitals (2022-2030) ($MN)
- Table 8 Global Aminophylline Market Outlook, By Clinics (2022-2030) ($MN)
- Table 9 Global Aminophylline Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
- Table 10 Global Aminophylline Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
- Table 11 Global Aminophylline Market Outlook, By Online Pharmacies (2022-2030) ($MN)
- Table 12 Global Aminophylline Market Outlook, By Application (2022-2030) ($MN)
- Table 13 Global Aminophylline Market Outlook, By Asthma Treatment (2022-2030) ($MN)
- Table 14 Global Aminophylline Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) Treatment (2022-2030) ($MN)
- Table 15 Global Aminophylline Market Outlook, By Infant Apnea (2022-2030) ($MN)
- Table 16 Global Aminophylline Market Outlook, By Other Applications (2022-2030) ($MN)
- Table 17 North America Aminophylline Market Outlook, By Country (2022-2030) ($MN)
- Table 18 North America Aminophylline Market Outlook, By Route of Administration (2022-2030) ($MN)
- Table 19 North America Aminophylline Market Outlook, By Oral (2022-2030) ($MN)
- Table 20 North America Aminophylline Market Outlook, By Intravenously (2022-2030) ($MN)
- Table 21 North America Aminophylline Market Outlook, By Injections (2022-2030) ($MN)
- Table 22 North America Aminophylline Market Outlook, By Distribution Channel (2022-2030) ($MN)
- Table 23 North America Aminophylline Market Outlook, By Hospitals (2022-2030) ($MN)
- Table 24 North America Aminophylline Market Outlook, By Clinics (2022-2030) ($MN)
- Table 25 North America Aminophylline Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
- Table 26 North America Aminophylline Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
- Table 27 North America Aminophylline Market Outlook, By Online Pharmacies (2022-2030) ($MN)
- Table 28 North America Aminophylline Market Outlook, By Application (2022-2030) ($MN)
- Table 29 North America Aminophylline Market Outlook, By Asthma Treatment (2022-2030) ($MN)
- Table 30 North America Aminophylline Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) Treatment (2022-2030) ($MN)
- Table 31 North America Aminophylline Market Outlook, By Infant Apnea (2022-2030) ($MN)
- Table 32 North America Aminophylline Market Outlook, By Other Applications (2022-2030) ($MN)
- Table 33 Europe Aminophylline Market Outlook, By Country (2022-2030) ($MN)
- Table 34 Europe Aminophylline Market Outlook, By Route of Administration (2022-2030) ($MN)
- Table 35 Europe Aminophylline Market Outlook, By Oral (2022-2030) ($MN)
- Table 36 Europe Aminophylline Market Outlook, By Intravenously (2022-2030) ($MN)
- Table 37 Europe Aminophylline Market Outlook, By Injections (2022-2030) ($MN)
- Table 38 Europe Aminophylline Market Outlook, By Distribution Channel (2022-2030) ($MN)
- Table 39 Europe Aminophylline Market Outlook, By Hospitals (2022-2030) ($MN)
- Table 40 Europe Aminophylline Market Outlook, By Clinics (2022-2030) ($MN)
- Table 41 Europe Aminophylline Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
- Table 42 Europe Aminophylline Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
- Table 43 Europe Aminophylline Market Outlook, By Online Pharmacies (2022-2030) ($MN)
- Table 44 Europe Aminophylline Market Outlook, By Application (2022-2030) ($MN)
- Table 45 Europe Aminophylline Market Outlook, By Asthma Treatment (2022-2030) ($MN)
- Table 46 Europe Aminophylline Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) Treatment (2022-2030) ($MN)
- Table 47 Europe Aminophylline Market Outlook, By Infant Apnea (2022-2030) ($MN)
- Table 48 Europe Aminophylline Market Outlook, By Other Applications (2022-2030) ($MN)
- Table 49 Asia Pacific Aminophylline Market Outlook, By Country (2022-2030) ($MN)
- Table 50 Asia Pacific Aminophylline Market Outlook, By Route of Administration (2022-2030) ($MN)
- Table 51 Asia Pacific Aminophylline Market Outlook, By Oral (2022-2030) ($MN)
- Table 52 Asia Pacific Aminophylline Market Outlook, By Intravenously (2022-2030) ($MN)
- Table 53 Asia Pacific Aminophylline Market Outlook, By Injections (2022-2030) ($MN)
- Table 54 Asia Pacific Aminophylline Market Outlook, By Distribution Channel (2022-2030) ($MN)
- Table 55 Asia Pacific Aminophylline Market Outlook, By Hospitals (2022-2030) ($MN)
- Table 56 Asia Pacific Aminophylline Market Outlook, By Clinics (2022-2030) ($MN)
- Table 57 Asia Pacific Aminophylline Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
- Table 58 Asia Pacific Aminophylline Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
- Table 59 Asia Pacific Aminophylline Market Outlook, By Online Pharmacies (2022-2030) ($MN)
- Table 60 Asia Pacific Aminophylline Market Outlook, By Application (2022-2030) ($MN)
- Table 61 Asia Pacific Aminophylline Market Outlook, By Asthma Treatment (2022-2030) ($MN)
- Table 62 Asia Pacific Aminophylline Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) Treatment (2022-2030) ($MN)
- Table 63 Asia Pacific Aminophylline Market Outlook, By Infant Apnea (2022-2030) ($MN)
- Table 64 Asia Pacific Aminophylline Market Outlook, By Other Applications (2022-2030) ($MN)
- Table 65 South America Aminophylline Market Outlook, By Country (2022-2030) ($MN)
- Table 66 South America Aminophylline Market Outlook, By Route of Administration (2022-2030) ($MN)
- Table 67 South America Aminophylline Market Outlook, By Oral (2022-2030) ($MN)
- Table 68 South America Aminophylline Market Outlook, By Intravenously (2022-2030) ($MN)
- Table 69 South America Aminophylline Market Outlook, By Injections (2022-2030) ($MN)
- Table 70 South America Aminophylline Market Outlook, By Distribution Channel (2022-2030) ($MN)
- Table 71 South America Aminophylline Market Outlook, By Hospitals (2022-2030) ($MN)
- Table 72 South America Aminophylline Market Outlook, By Clinics (2022-2030) ($MN)
- Table 73 South America Aminophylline Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
- Table 74 South America Aminophylline Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
- Table 75 South America Aminophylline Market Outlook, By Online Pharmacies (2022-2030) ($MN)
- Table 76 South America Aminophylline Market Outlook, By Application (2022-2030) ($MN)
- Table 77 South America Aminophylline Market Outlook, By Asthma Treatment (2022-2030) ($MN)
- Table 78 South America Aminophylline Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) Treatment (2022-2030) ($MN)
- Table 79 South America Aminophylline Market Outlook, By Infant Apnea (2022-2030) ($MN)
- Table 80 South America Aminophylline Market Outlook, By Other Applications (2022-2030) ($MN)
- Table 81 Middle East & Africa Aminophylline Market Outlook, By Country (2022-2030) ($MN)
- Table 82 Middle East & Africa Aminophylline Market Outlook, By Route of Administration (2022-2030) ($MN)
- Table 83 Middle East & Africa Aminophylline Market Outlook, By Oral (2022-2030) ($MN)
- Table 84 Middle East & Africa Aminophylline Market Outlook, By Intravenously (2022-2030) ($MN)
- Table 85 Middle East & Africa Aminophylline Market Outlook, By Injections (2022-2030) ($MN)
- Table 86 Middle East & Africa Aminophylline Market Outlook, By Distribution Channel (2022-2030) ($MN)
- Table 87 Middle East & Africa Aminophylline Market Outlook, By Hospitals (2022-2030) ($MN)
- Table 88 Middle East & Africa Aminophylline Market Outlook, By Clinics (2022-2030) ($MN)
- Table 89 Middle East & Africa Aminophylline Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
- Table 90 Middle East & Africa Aminophylline Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
- Table 91 Middle East & Africa Aminophylline Market Outlook, By Online Pharmacies (2022-2030) ($MN)
- Table 92 Middle East & Africa Aminophylline Market Outlook, By Application (2022-2030) ($MN)
- Table 93 Middle East & Africa Aminophylline Market Outlook, By Asthma Treatment (2022-2030) ($MN)
- Table 94 Middle East & Africa Aminophylline Market Outlook, By Chronic Obstructive Pulmonary Disease (COPD) Treatment (2022-2030) ($MN)
- Table 95 Middle East & Africa Aminophylline Market Outlook, By Infant Apnea (2022-2030) ($MN)
- Table 96 Middle East & Africa Aminophylline Market Outlook, By Other Applications (2022-2030) ($MN)
According to Stratistics MRC, the Global Aminophylline Market is accounted for $299.3 million in 2024 and is expected to reach $353.2 million by 2030 growing at a CAGR of 2.8% during the forecast period. Aminophylline is a bronchodilator used to treat asthma, chronic bronchitis, and other respiratory conditions by relaxing airway muscles and improving breathing. The aminophylline market is used in hospitals, clinics, and homecare settings, driven by the rising prevalence of respiratory diseases and growing healthcare needs. It can be administered orally, intravenously, or as an injection and requires careful dosage monitoring due to its narrow therapeutic range.
According to World Health Organization (WHO) data, respiratory diseases are a leading cause of death globally. Similarly, a 2023 article in the Economic Times highlighted a global increase in asthma cases, affecting approximately 339 million individuals.
Market Dynamics:
Driver:
Growing aging population
The growing aging population is a significant driver for the aminophylline market. As people age, they are more likely to develop chronic respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). Aminophylline, a bronchodilator, is commonly used to manage these conditions by relaxing the muscles in the airways and improving breathing. The increasing number of elderly individuals, who are more susceptible to respiratory disorders, drives the demand for aminophylline, thereby contributing to market growth.
Restraint:
Stringent regulatory requirements
Stringent regulatory requirements pose a significant restraint on the aminophylline market. The approval process for pharmaceuticals, including aminophylline, involves rigorous testing and compliance with safety and efficacy standards set by regulatory bodies such as the FDA and EMA. These stringent regulations can lead to delays in product approvals and increased costs for manufacturers. The need to adhere to these complex regulatory frameworks can hinder the timely introduction of new aminophylline formulations, thereby restraining market growth.
Opportunity:
Increasing prevalence of respiratory disorders
The increasing prevalence of respiratory disorders presents a substantial opportunity for the aminophylline market. Conditions such as asthma, COPD, and bronchitis are becoming more common due to factors like pollution, smoking, and lifestyle changes. Aminophylline is an effective treatment for these conditions, helping to alleviate symptoms and improve quality of life. The rising incidence of respiratory disorders drives the demand for aminophylline, creating opportunities for market expansion and the development of new therapeutic formulations.
Threat:
Side effects and safety concerns
Side effects and safety concerns associated with aminophylline use pose a threat to the market. Common side effects include nausea, vomiting, headaches, and insomnia, while severe reactions can include irregular heartbeats and seizures. These adverse effects can limit the use of aminophylline, as patients and healthcare providers may opt for alternative treatments with fewer risks. Addressing these safety concerns through improved formulations and patient education is crucial to maintaining market growth.
Covid-19 Impact:
The Covid-19 pandemic had a mixed impact on the aminophylline market. While the focus on respiratory health increased the demand for treatments like aminophylline, disruptions in supply chains and healthcare services affected production and distribution. The pandemic highlighted the importance of effective respiratory treatments, potentially driving future demand for aminophylline as healthcare systems recover and prioritize respiratory care.
The oral segment is expected to be the largest during the forecast period
The oral segment is anticipated to dominate the aminophylline market due to its convenience and widespread use. Oral administration of aminophylline, in the form of tablets or capsules, is preferred by patients for its ease of use and non-invasive nature. This segment's growth is driven by the increasing prevalence of chronic respiratory conditions and the preference for oral medications, which offer consistent dosing and improved patient compliance.
The online pharmacies segment is expected to have the highest CAGR during the forecast period
The online pharmacies segment is projected to have the highest CAGR due to the growing trend of digital healthcare and e-commerce. The convenience of purchasing medications online, coupled with the increasing use of digital platforms for healthcare services, drives the growth of this segment. Online pharmacies offer easy access to aminophylline, especially for patients in remote areas or those seeking discreet purchasing options, contributing to the segment's rapid expansion.
Region with largest share:
North America is positioned to dominate the aminophylline market due to its advanced healthcare infrastructure and high prevalence of respiratory disorders. The region's well-established medical research facilities and strong focus on innovative treatments drive the demand for aminophylline. Additionally, the presence of major pharmaceutical companies and substantial healthcare expenditure further bolster North America's leading position in the market.
Region with highest CAGR:
The Asia Pacific region anticipates rapid growth in the aminophylline market, driven by increasing urbanization, rising pollution levels, and a growing aging population. Countries like China and India are experiencing a surge in respiratory disorders, boosting the demand for effective treatments like aminophylline. Government initiatives to improve healthcare infrastructure and the expansion of pharmaceutical manufacturing capabilities contribute to the high CAGR in the Asia Pacific region.
Key players in the market
Some of the key players in Aminophylline Market include GlaxoSmithKline plc, Altor BioScience Corporation, Ono Pharmaceutical, Bayer AG, Teva Pharmaceutical Industries Ltd., Biosynth, Pfizer Inc., Abcam plc, Henry Schein, Inc., Medline Industries, Inc., Boehringer Ingelheim, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co., Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd. and Zydus Cadila.
Key Developments:
In May 2024, Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Theophylline Extended-Release Tablets, 300 mg and 450 mg (USRLD: Theo-Dur Extended-Release Tablets). Theophylline is used to treat asthma and chronic obstructive pulmonary disease (COPD). The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ, India.
In January 2023, Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, announces that the US Food and Drug Administration (FDA) has approved AstraZeneca's Airsupra (albuterol/budesonide, formerly known as PT027) for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.
Route of Administrations Covered:
- Oral
- Intravenously
- Injections
Distribution Channels Covered:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Retail Pharmacies
- Online Pharmacies
Applications Covered:
- Asthma Treatment
- Chronic Obstructive Pulmonary Disease (COPD) Treatment
- Infant Apnea
- Other Applications
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Aminophylline Market, By Route of Administration
- 5.1 Introduction
- 5.2 Oral
- 5.3 Intravenously
- 5.4 Injections
6 Global Aminophylline Market, By Distribution Channel
- 6.1 Introduction
- 6.2 Hospitals
- 6.3 Clinics
- 6.4 Ambulatory Surgical Centers
- 6.5 Retail Pharmacies
- 6.6 Online Pharmacies
7 Global Aminophylline Market, By Application
- 7.1 Introduction
- 7.2 Asthma Treatment
- 7.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment
- 7.4 Infant Apnea
- 7.5 Other Applications
8 Global Aminophylline Market, By Geography
- 8.1 Introduction
- 8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
- 8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
- 8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa
9 Key Developments
- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies
10 Company Profiling
- 10.1 GlaxoSmithKline plc
- 10.2 Altor BioScience Corporation
- 10.3 Ono Pharmaceutical
- 10.4 Bayer AG
- 10.5 Teva Pharmaceutical Industries Ltd.
- 10.6 Biosynth
- 10.7 Pfizer Inc.
- 10.8 Abcam plc
- 10.9 Henry Schein, Inc.
- 10.10 Medline Industries, Inc.
- 10.11 Boehringer Ingelheim
- 10.12 Novartis AG
- 10.13 Sanofi S.A.
- 10.14 AstraZeneca plc
- 10.15 Merck & Co., Inc.
- 10.16 Mylan N.V.
- 10.17 Sun Pharmaceutical Industries Ltd.
- 10.18 Cipla Ltd.
- 10.19 Dr. Reddy's Laboratories Ltd.
- 10.20 Zydus Cadila
